Evidence map›Paper›PMID 28959067›Full record

ArticleGhana medical journal2017

Hepatitis B virus surface antigen and antibody markers in children at a major paediatric hospital after the pentavalent DTP-HBV-Hib vaccination.

Thomas Apiung, Thomas A Ndanu, Julius Aa Mingle, Kwamena Wc Sagoe

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ghana medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03897946 (Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03897946 phase4completednot on this mapstarted 2019, after this paper: background citation

Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2019 to 2021Enrolled569ConditionsHepatitis BArmsBirth dose hepatitis B vaccine
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Thomas ApiungClinical Virology Laboratory, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
Thomas A NdanuSchool of Medicine & Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana.
Julius Aa MingleClinical Virology Laboratory, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
Kwamena Wc SagoeClinical Virology Laboratory, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
University of Ghana · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe knowledge about outcomes of infant vaccination against HBV infections using the DPT-HepB-Hib vaccine in Ghana is limited. This study therefore investigated the levels of immunity to HBV among children who received the DPT-HepB-Hib vaccine and HBsAg carriage in non-responders. Correlates for non-response or poor response were also investigated.

methodsCross-sectional study. A major paediatric hospital in Accra. Four hundred and twenty four children between the ages of 5 to 32 months who had completed the full vaccination schedule for the DPT-HepB-Hib vaccine.

resultsOf the 424 children, 358 (84.4%) developed anti-HBs while 340 (80.2%) developed ≥10 mIU/ml anti-HBs (sero-protection) and 3 had HBsAg. A binary logistic regression analysis showed that younger children were associated with sero-conversion (p=.022) and sero-protection (p=.021). For anti-HBs titres ≥100 mIU/ml age was a weaker but significant contributor (p=.041), as compared to the number of vaccines from different manufacturers the child used (p=.028). The mean age of those who used a single type of vaccine was higher (14.75 ± 6.056 months; n=268) than those who used vaccines from two or more manufacturers (11.96 ± 4.645 months; n=156), p= <.001 (CI: -3.897 - 1.688), an indication that efforts to procure vaccine from same source when it was initially introduced are waning.

conclusionsThere is still a residual possibility of infection with HBV in spite of infant vaccination. In the light of possible loss of anamnestic response over time, there is the need to consider a birth dose for HBV vaccination for all neonates or booster dose for infants who may not have received the vaccine at birth. Using vaccines from a single manufacturer is recommended.

fundingNone declared.

Indexed as

Antibodies, BacterialChild, PreschoolCross-Sectional StudiesDiphtheria-Tetanus-Pertussis VaccineFemaleGhanaHaemophilus VaccinesHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesHospitals, PediatricHumansImmunization ScheduleInfantLogistic ModelsMaleAntibodies, Bacterialdiphtheria-tetanus-acellular pertussis-Hib-hepatitis B vaccineDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B Vaccineshepatitis B virusInfantsurface antibodysurface antigenvaccination

Identifiers

PMID28959067
PMCPMC5611951
OpenAlexW2611726282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.